MEDI3617

DRUG2 trials

Sponsors

MedImmune LLC, F. Stephen Hodi, MD

Conditions

Advanced Recurrent Ovarian TumorsAdvanced Solid TumorsMetastatic Melanoma

Phase 1

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors

CompletedNCT01248949

MedImmune LLCAdvanced Recurrent Ovarian Tumors, Advanced Solid Tumors

Start: 2010-10-31End: 2015-10-31Updated: 2017-03-29

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

CompletedNCT02141542

F. Stephen Hodi, MDMetastatic Melanoma

Start: 2014-05-31End: 2020-09-23Updated: 2023-05-01

Related Papers

Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial

Journal for ImmunoTherapy of Cancer2021-11-0116 citations

A phase 1 study of MEDI3617, a selective angiopoietin-2 inhibitor, alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors.

Journal of Clinical Oncology2014-05-202 citations